TY - JOUR
T1 - Age Patterns of HSV-2 Incidence and Prevalence in Two Ugandan Communities
T2 - A Catalytic Incidence Model Applied to Population-Based Seroprevalence Data
AU - the Rakai Health Sciences Program
AU - Whittles, Lilith K.
AU - Galiwango, Ronald M.
AU - Mpagazi, Josephine
AU - Tobian, Aaron A.R.
AU - Ssekubugu, Robert
AU - Jackson, Jade
AU - Peer, Austin D.
AU - Kennedy, Caitlin
AU - Nakalanzi, Margaret
AU - Ndyanabo, Anthony
AU - Kigozi, Godfrey
AU - Chang, Larry W.
AU - Serwadda, David
AU - Manabe, Yukari C.
AU - Gaydos, Charlotte A.
AU - Laeyendecker, Oliver
AU - Quinn, Thomas C.
AU - Reynolds, Steven J.
AU - Kagaayi, Joseph
AU - Eaton, Jeffrey W.
AU - Grabowski, M. Kate
N1 - Publisher Copyright:
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
PY - 2023/11/1
Y1 - 2023/11/1
N2 - Background. Herpes simplex virus type 2 (HSV-2) is an incurable sexually transmitted infection associated with increased risk of acquiring and transmitting human immunodeficiency virus (HIV). HSV-2 is highly prevalent in sub-Saharan Africa, but population-level estimates of incidence are sparse. Methods. We measured HSV-2 prevalence from cross-sectional serological data among adults aged 18–49 years in 2 south-central Uganda communities (fishing, inland). We identified risk factors for seropositivity, then inferred age patterns of HSV-2 with a Bayesian catalytic model. Results. HSV-2 prevalence was 53.6% (n = 975/1819; 95% confidence interval, 51.3%–55.9%). Prevalence increased with age, was higher in the fishing community, and among women, reaching 93.6% (95% credible interval, 90.2%–96.6%) by age 49 years. Factors associated with HSV-2 seropositivity included more lifetime sexual partners, HIV positive status, and lower education. HSV-2 incidence peakied at age 18 years for women and 19–20 years for men. HIV prevalence was up to 10-fold higher in HSV-2–positive individuals. Conclusions. HSV-2 prevalence and incidence were extremely high, with most infections occurring in late adolescence. Interventions against HSV-2, such as future vaccines or therapeutics, must target young populations. Remarkably higher HIV prevalence among HSV-2–positive individuals underscores this population as a priority for HIV prevention.
AB - Background. Herpes simplex virus type 2 (HSV-2) is an incurable sexually transmitted infection associated with increased risk of acquiring and transmitting human immunodeficiency virus (HIV). HSV-2 is highly prevalent in sub-Saharan Africa, but population-level estimates of incidence are sparse. Methods. We measured HSV-2 prevalence from cross-sectional serological data among adults aged 18–49 years in 2 south-central Uganda communities (fishing, inland). We identified risk factors for seropositivity, then inferred age patterns of HSV-2 with a Bayesian catalytic model. Results. HSV-2 prevalence was 53.6% (n = 975/1819; 95% confidence interval, 51.3%–55.9%). Prevalence increased with age, was higher in the fishing community, and among women, reaching 93.6% (95% credible interval, 90.2%–96.6%) by age 49 years. Factors associated with HSV-2 seropositivity included more lifetime sexual partners, HIV positive status, and lower education. HSV-2 incidence peakied at age 18 years for women and 19–20 years for men. HIV prevalence was up to 10-fold higher in HSV-2–positive individuals. Conclusions. HSV-2 prevalence and incidence were extremely high, with most infections occurring in late adolescence. Interventions against HSV-2, such as future vaccines or therapeutics, must target young populations. Remarkably higher HIV prevalence among HSV-2–positive individuals underscores this population as a priority for HIV prevention.
KW - HSV-2
KW - catalytic model
KW - incidence
KW - population-based study
KW - prevalence
UR - http://www.scopus.com/inward/record.url?scp=85176496029&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85176496029&partnerID=8YFLogxK
U2 - 10.1093/infdis/jiad113
DO - 10.1093/infdis/jiad113
M3 - Article
C2 - 37079374
AN - SCOPUS:85176496029
SN - 0022-1899
VL - 228
SP - 1198
EP - 1207
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 9
ER -